ReviewThe Journal of international medical research2025
In and outside the spotlight: Nanomedicine in the treatment of osteoporosis.
Review in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, a high-incidence chronic disease, is known to cause physical pain, even leading to disability of patients, and creates a vast social burden. To improve the shortcomings of the current clinical osteoporosis treatment drugs, several studies have designed a multitude of nanomedicines to optimize traditional drugs based on the TOP-DOWN design. Fascinating nanomedicine designs are breathing vitality into traditional osteoporosis drugs. However, considering the unique pathological characteristics of osteoporosis and clinical treatment needs, we should also pay attention to the problems outside the spotlight. Here, we reviewed the current clinical osteoporosis treatment drugs, summarized their limitations, and generalized the nanomedicines designed based on the TOP-DOWN strategy for the mentioned deficiencies. In addition, we explored the issues outside the spotlight of the nanomedicine design for the treatment of osteoporosis because of the gap between laboratory design strategy and clinical demands and then determined the rational design of nanomedicines for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.